AIM ImmunoTech (AIM) 10-Q 13 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-27072
Entity Registrant Name	AIM IMMUNOTECH INC.
Entity Central Index Key	0000946644
Entity Tax Identification Number	52-0845822
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2117 SW Highway 484
Entity Address, City or Town	Ocala
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34473
City Area Code	(352)
Local Phone Number	448-7797
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AIM
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,048,822

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 28,989,000	$ 32,093,000
Marketable securities	15,554,000	16,175,000
Funds receivable from New Jersey net operating loss	1,641,000	1,641,000
Prepaid expenses and other current assets	296,000	304,000
Assets held for sale	3,900,000
Total current assets	50,380,000	50,213,000
Property and equipment, net	137,000	4,047,000
Right of use asset, net	144,000	149,000
Patent and trademark rights, net	1,988,000	1,974,000
Other assets	1,506,000	1,316,000
Total assets	54,155,000	57,699,000
Current liabilities:
Accounts payable	378,000	198,000
Accrued expenses	328,000	438,000
Current portion of operating lease liability	60,000	37,000
Total current liabilities	766,000	673,000
Long-term liabilities:
Operating lease liability	84,000	112,000
Redeemable warrants	4,000	35,000
Commitments and contingencies (Notes 12, 13 and 14)
Stockholders’ equity:
Series B Convertible Preferred Stock, stated value $1,000 per share, 715 issued and outstanding	715,000	715,000
Common Stock, par value $0.001 per share, authorized 350,000,000 shares; 47,994,672 issued and outstanding	48,000	48,000
Additional paid-in capital	417,459,000	417,217,000
Accumulated deficit	(364,921,000)	(361,101,000)
Total stockholders’ equity	53,301,000	56,879,000
Total liabilities and stockholders’ equity	$ 54,155,000	$ 57,699,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	47,994,672	47,994,672
Common stock, shares outstanding	47,994,672	47,994,672
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 1,000	$ 1,000
Preferred stock, shares, issued	715	715
Preferred stock, shares, outstanding	715	715

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Total Revenues	$ 33	$ 28
Costs and Expenses:
Production costs	77	237
Research and development	1,036	1,424
General and administrative	2,072	2,112
Total Costs and Expenses	3,185	3,773
Operating loss	(3,152)	(3,745)
(Loss) on investments	(934)
Interest and other income	45	72
Interest expense and other finance costs		(50)
Redeemable warrants valuation adjustment	31	(37)
Gain from sale of income tax operating losses	190	181
Net Loss	(3,820)	(3,579)
Other comprehensive loss
Reclassification adjustment for realized investment loss		2
Change in unrealized loss on marketable securities available for sale		(163)
Net comprehensive loss	$ (3,820)	$ (3,740)
Basic and diluted loss per share	$ (0.08)	$ (0.08)
Weighted average shares outstanding basic and diluted	47,994,672	45,726,855
Clinical Treatment Programs US [Member]
Revenues:
Total Revenues	$ 33	$ 28
Clinical Treatment Programs Europe [Member]
Revenues:
Total Revenues

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020		$ 42	$ 402,541	$ (47)	$ (341,974)	$ 61,294
Beginning balance, shares at Dec. 31, 2020	732	42,154,371
Equity-based compensation			526			526
Net comprehensive loss				(161)	(3,579)	(3,740)
Common Stock issuance, net of costs		$ 6	12,881			12,887
Common stock issuance, net of costs, shares		5,678,626
Series B preferred shares converted to Common shares			7
Series B preferred shares converted to Common shares, shares	(7)
Ending balance, value at Mar. 31, 2021		$ 48	415,995	(208)	(345,553)	70,967
Ending balance, shares at Mar. 31, 2021	725	47,832,997
Beginning balance, value at Dec. 31, 2020		$ 42	402,541	(47)	(341,974)	61,294
Beginning balance, shares at Dec. 31, 2020	732	42,154,371
Ending balance, value at Dec. 31, 2021		$ 48	417,217		(361,101)	56,879
Ending balance, shares at Dec. 31, 2021	715	47,994,672
Equity-based compensation			242			242
Net comprehensive loss					(3,820)	(3,820)
Ending balance, value at Mar. 31, 2022		$ 48	$ 417,459		$ (364,921)	$ 53,301
Ending balance, shares at Mar. 31, 2022	715	47,994,672

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (3,820,000)	$ (3,579,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	10,000	162,000
Redeemable warrants valuation adjustment	(31,000)	37,000
Amortization of patent, trademark rights	19,000	65,000	$ 116,000
Changes in ROU assets	5,000	11,000
Loss on available for sale marketable securities	19,000	2,000
Gain from sale of income tax operating losses	(190,000)	(181,000)
Equity-based compensation	242,000	526,000
Unrealized loss on marketable securities	915,000
Amortization of finance and debt issuance costs		36,000
Change in assets and liabilities:
Prepaid expenses and other current assets and other non current assets	8,000	26,000
Lease liability	(5,000)	(11,000)
Accounts payable	180,000	(194,000)
Accrued expenses	(110,000)	55,000
Net cash used in operating activities	(2,758,000)	(3,045,000)
Cash flows from investing activities:
Proceeds from sale of marketable securities	407,000	2,039,000
Purchase of marketable securities	(720,000)	(1,151,000)
Purchase of patent and trademark rights	(33,000)	(365,000)
Net cash (used in) provided by investing activities	(346,000)	523,000
Cash flows from financing activities:
Financing obligation payments		(93,000)
Proceeds from sale of stock, net of issuance costs		12,887,000
Net cash provided by financing activities		12,794,000
Net (decrease) increase in cash and cash equivalents	(3,104,000)	10,272,000
Cash and cash equivalents at beginning of period	32,093,000	38,501,000	38,501,000
Cash and cash equivalents at end of period	28,989,000	48,773,000	$ 32,093,000
Supplemental disclosures of non-cash investing and financing cash flow information:
Conversion of Series B preferred		$ 7,000

Business and Basis of Presentat

Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Note 1: Business and Basis of Presentation AIM ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “the Company”,) are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. The Company has established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. Our flagship products are Ampligen® (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon alfa-n3). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”). Our primary present business focus involves Ampligen. Ampligen represents a dsRNA being developed for globally important cancers, viral diseases and disorders of the immune system. The Company is currently proceeding primarily in four areas: ● A randomized controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced pancreatic cancer patients. ● Evaluate Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to check point inhibitors. ● Exploring Ampligen’s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof. ● Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”) and fatigue and/or difficulty thinking/concentrating as the predominate Post-COVID conditions (as referenced on CDC website Sept. 16, 2021). The Company is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. The Company intends that priority clinical work be conducted in FDA or EMA authorized trials which could support a potential future New Drug Application (“NDA”). However, AIM’s antiviral experimentation is designed to accumulate additional preliminary data supporting their hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection. Accordingly, AIM will conduct antiviral programs in those venues most readily available and able to generate valid proof-of-concept data, including foreign venues. In May 2021, AIM exercised the option to re-purchase the New Brunswick manufacturing facility, pursuant to the terms of the March 2018 sale and lease-back agreement. The Company thereafter sold certain equipment and machinery that they determined to be obsolete and no longer needed for current or future manufacturing. Then, on March 3, 2022, AIM entered into an Agreement of Sale and Purchase with Acellories, Inc. as purchaser pursuant to which the Company will sell the property for $ 3.9 million. The buyer has a mortgage contingency, with the clause expiring on June 1, 2022. Assuming that condition is met, we would anticipate closing on or before July 1, 2022. Moving forward, AIM will require one or more Contract Manufacturing Organizations (“CMO”) to produce Ampligen API. While AIM believes they have sufficient Ampligen API to meet their current needs, they are also continually exploring new efficiencies so as to maximize their ability to fulfill future obligations. In this regard, in April 2021, AIM approved a proposal from Polysciences Inc. (“Polysciences”) for the manufacture of Poly I and Poly C 12 In the opinion of management, all adjustments necessary for a fair presentation of such consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year. The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2021 and 2020, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 31, 2022.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Note 2: Net Loss Per Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 2,453,782 1,672,825

Equity-Based Compensation

Equity-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Equity-Based Compensation	Note 3: Equity-Based Compensation The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. During the three months ended March 31, 2022 there were 300,000 no Stock option for employees’ activity during the three months ended March 31, 2022, is as follows: Stock option activity for employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2022 1,498,798 $ 4.22 9.11 $ — Granted 150,000 0.70 9.75 — Forfeited — 233.54 — — Expired (739 ) — — — Outstanding March 31, 2022 1,648,059 $ 3.80 8.94 $ — Vested and expected to vest March 31, 2022 1,648,059 $ 3.80 8.94 $ — Exercisable March 31, 2022 1,216,894 $ 3.15 6.08 $ — Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2022 412,500 $ 4.15 5.85 $ — Granted 150,000 0.70 9.75 — Expired (739 ) 233.54 — — Vested (130,596 ) 1.52 9.88 — Unvested March 31, 2022 431,165 $ 2.69 7.32 $ — Stock option activity for non-employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2022 279,723 $ 6.12 7.93 $ — Granted 150,000 0.70 9.75 — Forfeited — — — — Expired — — — — Outstanding March 31, 2022 429,723 $ 4.23 8.40 $ — Vested and expected to vest March 31, 2022 429,723 $ 4.23 8.40 $ — Exercisable March 31, 2022 222,770 $ 6.05 7.96 $ — Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2022 97,831 $ 3.89 7.82 $ — Granted 150,000 0.70 9.75 — Expired — — — — Vested (40,878 ) 1.35 — — Unvested March 31, 2022 206,953 $ 3.66 7.60 $ — Stock-based compensation expense was approximately $ 242,000 526,000 As March 31, 2022, and 2021, respectively, there was approximately $ 729,000 914,000

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Note 4: Marketable Securities Marketable securities consist of mutual funds. At March 31, 2022 and December 31, 2021, it was determined that none of the marketable securities had an other-than-temporary impairment. At March 31, 2022 and December 31, 2021, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 11: Fair Value). As of March 31, 2022, and December 31, 2021 the Company held $ 15,554,000 16,175,000 Mutual Funds classified as available for sale consisted of: Schedule of Available for Sale March 31, 2022 (in thousands) Securities Fair Short-Term Mutual Funds $ 15,554 $ 15,554 Totals $ 15,554 $ 15,554 Schedule of Equity Securities March 31, 2022 (in thousands) Securities Net losses recognized during the period on equity securities $ (934 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (19 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (915 ) Mutual Funds classified as available for sale consisted of: December 31, 2021 (in thousands) Securities Fair Short-Term Mutual Funds $ 16,175 $ 16,175 Totals $ 16,175 $ 16,175 December 31, 2021 (in thousands) Securities Net losses recognized during the period on equity securities $ (88 ) Less: Net gains and losses recognized during the period on equity securities sold during the period — Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (88 )

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses	Note 5: Accrued Expenses Accrued expenses consist of the following: Schedule of Accrued Expenses March 31, 2022 December 31, 2021 (in thousands) March 31, 2022 December 31, 2021 Compensation $ 14 $ 1 Professional fees 94 169 Clinical trial expenses 61 61 Other expenses 159 207 Accrued expenses $ 328 $ 438

Property and Equipment, net

Property and Equipment, net	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Note 6: Property and Equipment, net Schedule of Property and Equipment March 31, 2022 December 31, 2021 (in thousands) March 31, 2022 December 31, 2021 Land, buildings and improvements $ — $ 3,900 Furniture, fixtures, and equipment 2,353 2,353 Total property and equipment 2,353 6,253 Less: accumulated depreciation (2,216 ) (2,206 ) Property and equipment, net $ 137 $ 4,047 Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from three to thirty-nine years. Depreciation expense for the periods ending March 31, 2022 and March 31, 2021 was $ 10,000 and $ 162,000 , respectively. The Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $ 1,800,000

Patents

Patents	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 7: Patents Schedule of Patents, Trademark Rights December 31, 2020 $ 1,498 Acquisitions 592 Amortization (116 ) December 31, 2021 $ 1,974 Acquisitions 33 Amortization (19 ) March 31, 2022 $ 1,988 Patents and trademarks are stated at cost and are amortized using the straight-line method of the estimated useful life of 17 Amortization of patents and trademarks for each of the next five years and thereafter is as follows: Schedule of Amortization of Patents and Trademarks Year Ending December 31, 2022 $ 59 2023 153 2024 177 2025 199 2026 235 Thereafter 1,165 Total $ 1,988

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Equity	Note 8: Stockholders’ Equity (a) Preferred Stock The Company is authorized to issue 5,000,000 0.01 250,000 8,000 1,000 The Company is authorized to issue 8,000 no 1,000 715 715 114 Pursuant to a registration statement relating to a rights offering declared effective by the SEC on February 14, 2019, AIM distributed to its holders of common stock and to holders of certain options and warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase one unit, at a subscription price of $ 1,000 1,000 8.80 114 8.80 five years 4,700,000 (b) Common Stock The Company has authorized shares of 350,000,000 8,000,000 350,000,000 On July 7, 2020, the board of directors approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $ 500,000 500,000 During the three months ended March 31, 2022, the Company issued a total of 0 During the twelve months ended December 31, 2021, the Company issued a total of 132,238 1.16 2.35 205,000 On September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the “Offering”) of (i) 1,740,550 7,148,310 8,888,860 a Representative’s Warrant to purchase up to an aggregate of 266,665 . The shares of Common Stock and Warrants were sold at a combined Offering price of $ 0.90 0.99 0.899 7,200,000 15,000 On July 19, 2019, the Company entered into a new Equity Distribution Agreement (the “2019 EDA”) with Maxim Group LLC (“Maxim”), pursuant to which it could sell, from time to time, shares of its Common Stock through Maxim, as agent (the “Offering”). The 2019 EDA replaced a prior EDA with Maxim. For the year ended December 31, 2020, the Company sold 20,444,807 53,936,615 3.5 1,888,727 5,665,731 13,301,526 3.5 465,533 The 2018 Equity Incentive Plan, effective September 12, 2018, authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of 7,000,000 10 300,000 .70 ten years 613,512 1.11 1.71 ten years 675,000 1.85 1.96 ten years As of both periods March 31, 2022, and December 31, 2021, there were 47,994,672

Cash and Cash Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 9 Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2022
Recent Accounting Pronouncements
Recent Accounting Pronouncements	Note 10: Recent Accounting Pronouncements During the first quarter of 2022 accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Fair Value

Fair Value	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value	Note 11: Fair Value Fair Value The Company is required under U.S. GAAP to disclose information about the fair value of all the Company’s financial instruments, whether or not these instruments are measured at fair value on the Company’s consolidated balance sheets. The Company estimates that the fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to the short-term maturities of these items. The Company also has certain warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the redeemable warrants (“Warrants”) related to the Company’s February 2017, June 2017, April 2018, and March 2019 common stock and warrant issuance, are calculated using a Monte Carlo Simulation. While the Monte Carlo Simulation is one of a number of possible pricing models, the Company has determined it to be industry accepted and fairly presented the fair value of the Warrants. As an additional factor to determine the fair value of the Put’s liability, the occurrence probability of a Fundamental Transaction event was factored into the valuation. The Company recomputes the fair value of the Warrants at the issuance date and the end of each quarterly reporting period. Such value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions or the numbers input based on such assumptions, the resulting fair value could be materially different. The Company utilized the following assumptions to estimate the fair value of the February 2017 Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants March 31, December 31, 2022 2021 Underlying price per share $ 1.06 $ 0.92 Exercise price per share $ 30.25 33.00 $ 30.25 33.00 Risk-free interest rate 0.71 0.74 0.22 0.23 Expected holding period 0.34 - 0.35 0.58 0.60 Expected volatility 85 % 45 % Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the June 2017 Warrants: March 31, December 31, 2022 2021 Underlying price per share $ 1.06 $ 0.92 Exercise price per share $ 27.50 $ 27.50 Risk-free interest rate 0.35 % 0.15 % Expected holding period 0.17 0.42 Expected volatility 85 % 50 % Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the April 2018 Warrants: March 31, December 31, 2022 2021 Underlying price per share $ 1.06 $ 0.92 Exercise price per share $ 17.16 $ 17.16 Risk-free interest rate 2.00 % 0.67 % Expected holding period 1.57 1.81 Expected volatility 70 % 120 % Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants: March 31, December 31, 2022 2021 Underlying price per share $ 1.06 $ 0.92 Exercise price per share $ 8.80 $ 8.80 Risk-free interest rate 2.24 % 0.78 % Expected holding period 1.94 2.19 Expected volatility 75 % 125 % Expected dividend yield — — The significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are: (i) Risk-Free Interest Rate (ii) Expected Holding Period (iii) Expected Volatility (iv) Expected Dividend Yield 0 (v) Expected Probability of a Fundamental Transaction. 1. The Company only has one product that is FDA approved but is currently not available for commercial sales. 2. The Company will have to perform additional clinical trials for FDA approval of its flagship product. 3. Industry and market conditions continue to include uncertainty, adding risk to any transaction. 4. Available capital for a potential buyer in a cash transaction continues to be limited. 5. The nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research & Development. 6. The Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction at their manufacturing facility; and 7. The Company’s Rights Agreement and Executive Agreements make it less attractive to a potential buyer. With the above factors utilized in analysis of the likelihood of the Put’s potential Liability, the Company estimated the range of probabilities related to a Put right being triggered as: Schedule of Range of Probabilities Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 % The Monte Carlo Simulation has incorporated a 5.0% probability of a Fundamental Transaction to date for the life of the securities. (vi) Expected Timing of Announcement of a Fundamental Transaction. (vii) Expected 100 Day Volatility at Announcement of a Fundamental Transaction 100 (viii) Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction (ix) Expected Time Between Announcement and Consummation of a Fundamental Transaction. While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the numbers input change from period to period (e.g., the actual historical prices input for the relevant period). The carrying amount and estimated fair value of the above Warrants was approximately $ 4,000 35,000 The Company applies FASB ASC 820 (formerly Statement No. 157 Fair Value Measurements FASB ASC 820-10-35-37 (formerly SFAS No. 157) establishes a valuation hierarchy based on the transparency of inputs used in the valuation of an asset or liability. Classification is based on the lowest level of inputs that is significant to the fair value measurement. The valuation hierarchy contains three levels: 1. Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market. 2. Level 2 – Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market. 3. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. As of March 31, 2022, the Company has classified the warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants. The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as: Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) As of March 31, 2022 Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 15,554 $ 15,554 $ — $ — Liabilities: Redeemable warrants $ 4 — $ — 4 (in thousands) As of December 31, 2021 Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 16,175 $ 16,175 $ — $ — Liabilities: Redeemable warrant $ 35 — — $ 35 The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows (in thousands): Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis Redeemable warrants: Balance at December 31, 2021 $ 35 Fair value adjustments (31 ) Balance at March 31, 2022 $ 4 The table below presents the balances of assets and liabilities measured at fair value on a nonrecurring basis by level within the hierarchy as: Schedule of Assets and Liabilities Measured at Fair Value on a NonRecurring Basis (in thousands) Total Level 1 Level 2 Level 3 Total Gains (Losses) Assets: Long lived assets held and used (a) $ 3,900 $ — $ — $ 3,900 $ 1,800 (a) In accordance with Subtopic 360-10, long-lived assets held and used with a carrying amount of $ 5,700,000 3,900,000 1,800,000

Financing Obligation Arising fr

Financing Obligation Arising from Sale Leaseback Transaction	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Financing Obligation Arising from Sale Leaseback Transaction	Note 12: Financing Obligation Arising from Sale Leaseback Transaction On March 16, 2018, the Company sold land and a building for $ 4,080,000 lease the property back for ten years at $408,000 per year for two years through March 31, 2020. The lease payments would increase 2.5% per year for the next three years through March 31, 2023, and the lease payments would increase 3% for the remaining five years 73,314 five years 17.05 125 On May 13, 2021, the Company completed its repurchase of the property for cash of $ 4,732,637 Interest expense relating to this financing agreement was $ 0 14,000

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases
Leases	Note 13: Leases The Company leases office and storage space, and other equipment under non-cancellable operating leases with initial terms typically ranging from 1 5 Leases The Company’s lease terms may include options to extend or terminate the lease. The Company exercises judgment to determine the term of those leases when extension or termination options are present and include such options in the calculation of the lease term when it is reasonably certain that it will exercise those options. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs, are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease liability, while any variable portion would be recognized as variable lease expenses, when incurred. Variable payments made to third parties for these, or similar costs, such as utilities, are not included in the calculation of lease payments. At lease commencement, lease-related assets and liabilities are measured at the present value of future lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company exercises judgment in determining the incremental borrowing rate based on the information available when the lease commences to measure the present value of future payments. Operating leases are included in other assets, current operating lease obligations, and operating lease obligations (less current portion) on the Company’s consolidated balance sheet. Short term leases with an initial term of 12 months or less are not presented on the balance sheet with expense recognized as incurred. The Company entered into a Lease Agreement for a term of five years September 14, 2020 1,415 On June 13, 2018, the Company entered into a Lease Agreement for a term of six years July 1, 2018 3,000 3 2,100 2,785 On May 1, 2019, the Company entered into a Lease Agreement for a term of three years commencing on May 1, 2019 , pursuant to which the Company agreed to lease approximately 3,000 rentable square feet. The base rent is $ 2,500 per month for the term of the lease. On October 4, 2021, the Company executed a request to renew the lease for a one-year term as defined in the Lease Agreement. The request was accepted and the one-year term commenced on April 30, 2022. On February 17, 2022, the Company entered into a Lease Agreement for a term of two years commencing on March 1, 2022, pursuant to which the Company agreed to lease a Canon copier. The base rent is $ 322 per month for the term of the lease. The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably certain that the Company would exercise such options. The Company’s leases have remaining lease terms between 13 5 3.7 2.72 The Company has determined that the incremental borrowing rate is 10% Future minimum payments as of March 31, 2022, are as follows: Schedule of Operating lease Future Payments Year Ending December 31, 2022 $ 49 2023 60 2024 35 2025 14 Less imputed interest (14 ) Total 144 As of March 31, 2022, and December 31, 2021, the balance of the right of use assets was $ 144,000 149,000 144,000 149,000 17,000 67,000 3,000 12,000

Research, Consulting and Supply

Research, Consulting and Supply Agreements	3 Months Ended
	Mar. 31, 2022
Research Consulting And Supply Agreements
Research, Consulting and Supply Agreements	Note 14: Research, Consulting and Supply Agreements In January 2021, the Company entered into a Sponsor Agreement with the Centre for Human Drug Research (“CHDR”) for a Phase 1 clinical study to assess the safety, tolerability, and biological activity of Ampligen as a potential intranasal therapy. The Company has paid CHDR approximately $ 1,010,000 61,000 In April 2021, the Company approved a proposal from Polysciences Inc. (“Polysciences”) for the manufacture of our Poly I and Poly C12U polynucleotides and associated test methods at Polysciences’ Warrington, PA location to enhance our capacity to produce the polymer precursors to the drug Ampligen. The Company is working with Polysciences to negotiate and finalize both a Service Agreement and a Quality Agreement. For the year ended December 31, 2021 the Company has incurred an expense and paid Polysciences approximately $ 250,000 51,390 In April 2022, AIM executed a work order with Amarex Clinical Research LLC, our contract research organization, pursuant to which Amarex will manage a Phase 2 clinical trial in advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that the study will cost approximately $ 8.2 1.0 4.6

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 15: Subsequent Events None.

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity for employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2022 1,498,798 $ 4.22 9.11 $ — Granted 150,000 0.70 9.75 — Forfeited — 233.54 — — Expired (739 ) — — — Outstanding March 31, 2022 1,648,059 $ 3.80 8.94 $ — Vested and expected to vest March 31, 2022 1,648,059 $ 3.80 8.94 $ — Exercisable March 31, 2022 1,216,894 $ 3.15 6.08 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2022 412,500 $ 4.15 5.85 $ — Granted 150,000 0.70 9.75 — Expired (739 ) 233.54 — — Vested (130,596 ) 1.52 9.88 — Unvested March 31, 2022 431,165 $ 2.69 7.32 $ —
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity for non-employees: Schedule of Stock Option Activity Number of Weighted Weighted Aggregate Outstanding January 1, 2022 279,723 $ 6.12 7.93 $ — Granted 150,000 0.70 9.75 — Forfeited — — — — Expired — — — — Outstanding March 31, 2022 429,723 $ 4.23 8.40 $ — Vested and expected to vest March 31, 2022 429,723 $ 4.23 8.40 $ — Exercisable March 31, 2022 222,770 $ 6.05 7.96 $ —
Schedule of Unvested Stock Option Activity	Unvested stock option activity for non-employees: Schedule of Unvested Stock Option Activity Number of Weighted Weighted Aggregate Unvested January 1, 2022 97,831 $ 3.89 7.82 $ — Granted 150,000 0.70 9.75 — Expired — — — — Vested (40,878 ) 1.35 — — Unvested March 31, 2022 206,953 $ 3.66 7.60 $ —

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Available for Sale	Mutual Funds classified as available for sale consisted of: Schedule of Available for Sale March 31, 2022 (in thousands) Securities Fair Short-Term Mutual Funds $ 15,554 $ 15,554 Totals $ 15,554 $ 15,554 Mutual Funds classified as available for sale consisted of: December 31, 2021 (in thousands) Securities Fair Short-Term Mutual Funds $ 16,175 $ 16,175 Totals $ 16,175 $ 16,175
Schedule of Equity Securities	Schedule of Equity Securities March 31, 2022 (in thousands) Securities Net losses recognized during the period on equity securities $ (934 ) Less: Net gains and losses recognized during the period on equity securities sold during the period (19 ) Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (915 ) December 31, 2021 (in thousands) Securities Net losses recognized during the period on equity securities $ (88 ) Less: Net gains and losses recognized during the period on equity securities sold during the period — Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date $ (88 )

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: Schedule of Accrued Expenses March 31, 2022 December 31, 2021 (in thousands) March 31, 2022 December 31, 2021 Compensation $ 14 $ 1 Professional fees 94 169 Clinical trial expenses 61 61 Other expenses 159 207 Accrued expenses $ 328 $ 438

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Schedule of Property and Equipment March 31, 2022 December 31, 2021 (in thousands) March 31, 2022 December 31, 2021 Land, buildings and improvements $ — $ 3,900 Furniture, fixtures, and equipment 2,353 2,353 Total property and equipment 2,353 6,253 Less: accumulated depreciation (2,216 ) (2,206 ) Property and equipment, net $ 137 $ 4,047

Patents (Tables)

Patents (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents, Trademark Rights	Schedule of Patents, Trademark Rights December 31, 2020 $ 1,498 Acquisitions 592 Amortization (116 ) December 31, 2021 $ 1,974 Acquisitions 33 Amortization (19 ) March 31, 2022 $ 1,988
Schedule of Amortization of Patents and Trademarks	Amortization of patents and trademarks for each of the next five years and thereafter is as follows: Schedule of Amortization of Patents and Trademarks Year Ending December 31, 2022 $ 59 2023 153 2024 177 2025 199 2026 235 Thereafter 1,165 Total $ 1,988

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Assumptions to Estimate Fair Value of Warrants	The Company utilized the following assumptions to estimate the fair value of the February 2017 Warrants: Schedule of Assumptions to Estimate Fair Value of Warrants March 31, December 31, 2022 2021 Underlying price per share $ 1.06 $ 0.92 Exercise price per share $ 30.25 33.00 $ 30.25 33.00 Risk-free interest rate 0.71 0.74 0.22 0.23 Expected holding period 0.34 - 0.35 0.58 0.60 Expected volatility 85 % 45 % Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the June 2017 Warrants: March 31, December 31, 2022 2021 Underlying price per share $ 1.06 $ 0.92 Exercise price per share $ 27.50 $ 27.50 Risk-free interest rate 0.35 % 0.15 % Expected holding period 0.17 0.42 Expected volatility 85 % 50 % Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the April 2018 Warrants: March 31, December 31, 2022 2021 Underlying price per share $ 1.06 $ 0.92 Exercise price per share $ 17.16 $ 17.16 Risk-free interest rate 2.00 % 0.67 % Expected holding period 1.57 1.81 Expected volatility 70 % 120 % Expected dividend yield — — The Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants: March 31, December 31, 2022 2021 Underlying price per share $ 1.06 $ 0.92 Exercise price per share $ 8.80 $ 8.80 Risk-free interest rate 2.24 % 0.78 % Expected holding period 1.94 2.19 Expected volatility 75 % 125 % Expected dividend yield — —
Schedule of Range of Probabilities	Schedule of Range of Probabilities Range of Probability Probability Low 0.5 % Medium 1.0 % High 5.0 %
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as: Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (in thousands) As of March 31, 2022 Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 15,554 $ 15,554 $ — $ — Liabilities: Redeemable warrants $ 4 — $ — 4 (in thousands) As of December 31, 2021 Total Level 1 Level 2 Level 3 Assets: Marketable securities $ 16,175 $ 16,175 $ — $ — Liabilities: Redeemable warrant $ 35 — — $ 35
Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis	The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows (in thousands): Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis Redeemable warrants: Balance at December 31, 2021 $ 35 Fair value adjustments (31 ) Balance at March 31, 2022 $ 4
Schedule of Assets and Liabilities Measured at Fair Value on a NonRecurring Basis	The table below presents the balances of assets and liabilities measured at fair value on a nonrecurring basis by level within the hierarchy as: Schedule of Assets and Liabilities Measured at Fair Value on a NonRecurring Basis (in thousands) Total Level 1 Level 2 Level 3 Total Gains (Losses) Assets: Long lived assets held and used (a) $ 3,900 $ — $ — $ 3,900 $ 1,800 (a) In accordance with Subtopic 360-10, long-lived assets held and used with a carrying amount of $ 5,700,000 3,900,000 1,800,000

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases
Schedule of Operating lease Future Payments	Future minimum payments as of March 31, 2022, are as follows: Schedule of Operating lease Future Payments Year Ending December 31, 2022 $ 49 2023 60 2024 35 2025 14 Less imputed interest (14 ) Total 144

Business and Basis of Present_2

Business and Basis of Presentation (Details Narrative) $ in Millions	1 Months Ended
	May 31, 2021USD ($)
Acellories Inc [Member]
Sale of Stock, Consideration Received on Transaction	$ 3.9

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share	2,453,782	2,453,782
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share	1,672,825	1,672,825

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning of Period	1,498,798
Weighted Average Exercise Price Outstanding, beginning of Period	$ 4.22
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 11 months 8 days	9 years 1 month 9 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Number of Options, Granted	150,000
Weighted Average Exercise Price, Granted	$ 0.70
Weighted Average Remaining Contracted Term (years) Granted	9 years 9 months
Aggregate Intrinsic Value, Granted
Number of Options, Forfeited
Weighted Average Exercise Price, Forfeited	$ 233.54
Aggregate Intrinsic Value, Forfeited
Number of Options, Expired	(739)
Weighted Average Exercise Price, Forfeited
Aggregate Intrinsic Value, Expired
Number of Options Outstanding, Ending of Period	1,648,059	1,498,798
Weighted Average Exercise Price Outstanding, End of Period	$ 3.80	$ 4.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	1,648,059
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 3.80
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	8 years 11 months 8 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,216,894
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 3.15
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	6 years 29 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning of Period	279,723
Weighted Average Exercise Price Outstanding, beginning of Period	$ 6.12
Weighted Average Remaining Contracted Term (years) Outstanding	8 years 4 months 24 days	7 years 11 months 4 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Number of Options, Granted	150,000
Weighted Average Exercise Price, Granted	$ 0.70
Weighted Average Remaining Contracted Term (years) Granted	9 years 9 months
Aggregate Intrinsic Value, Granted
Aggregate Intrinsic Value, Forfeited
Aggregate Intrinsic Value, Expired
Number of Options Outstanding, Ending of Period	429,723	279,723
Weighted Average Exercise Price Outstanding, End of Period	$ 4.23	$ 6.12
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	429,723
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 4.23
Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest	8 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	222,770
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 6.05
Weighted Average Remaining Contracted Term (years), Exercisable at End of Period	7 years 11 months 15 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value

Schedule of Unvested Stock Opti

Schedule of Unvested Stock Option Activity (Details) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Granted	300,000	0
Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	412,500
Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price	$ 4.15
Average Remaining Contractual Term (years) Unvested, Beginning of Period			5 years 10 months 6 days
Share based Compensation Arrangement By Share based Payment Award Options Non-vested Aggregate Intrinsic Value
Number of Options, Granted	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.70
Average Remaining Contractual Term granted	9 years 9 months
Share based Compensation Arrangement By Share based Payment Award Options Non-vested Grants In Period Aggregate Intrinsic Value
Number of Options, Expired	(739)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Expired, Weighted Average Grant Date Fair Value	$ 233.54
Aggregate Intrinsic Value, Expired
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	(130,596)
Weighted Average Exercise Price, Vested	$ 1.52
Weighted Average Remaining Contracted Term (years) Vested	9 years 10 months 17 days
Aggregate Intrinsic Value, Vested
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	431,165		412,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance	$ 2.69		$ 4.15
Average Remaining Contractual Term (years) Unvested, End of Period	7 years 3 months 25 days
Share based Compensation Arrangement By Share based Payment Award Options Non-vested Aggregate Intrinsic Value
Number of Options, Expired	739
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	97,831
Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price	$ 3.89
Average Remaining Contractual Term (years) Unvested, Beginning of Period			7 years 9 months 25 days
Share based Compensation Arrangement By Share based Payment Award Options Non-vested Aggregate Intrinsic Value
Number of Options, Granted	150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.70
Average Remaining Contractual Term granted	9 years 9 months
Share based Compensation Arrangement By Share based Payment Award Options Non-vested Grants In Period Aggregate Intrinsic Value
Number of Options, Expired
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Expired, Weighted Average Grant Date Fair Value
Aggregate Intrinsic Value, Expired
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	(40,878)
Weighted Average Exercise Price, Vested	$ 1.35
Aggregate Intrinsic Value, Vested
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	206,953		97,831
Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance	$ 3.66		$ 3.89
Average Remaining Contractual Term (years) Unvested, End of Period	7 years 7 months 6 days
Share based Compensation Arrangement By Share based Payment Award Options Non-vested Aggregate Intrinsic Value
Number of Options, Expired

Equity-Based Compensation (Deta

Equity-Based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options, granted	300,000	0
Share based compensation expense	$ 242,000	$ 526,000
Unrecognized stock-based compensation cost	$ 729,000	914,000
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options, granted	150,000
Share based compensation expense	$ 242,000	$ 526,000

Schedule of Available for Sale

Schedule of Available for Sale (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Fair Value	$ 15,554,000	$ 16,175,000
Short-Term Investment	15,554,000	16,175,000
Mutual Funds [Member]
Marketable Securities [Line Items]
Fair Value	15,554,000	16,175,000
Short-Term Investment	$ 15,554,000	$ 16,175,000

Schedule of Equity Securities (

Schedule of Equity Securities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Net losses recognized during the period on equity securities	$ (934)	$ (88)
Less: Net gains and losses recognized during the period on equity securities sold during the period	(19)
Unrealized gains and losses recognized during the reporting period on equity securities still held at the reporting date	$ (915)	$ (88)

Marketable Securities (Details

Marketable Securities (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	$ 15,554,000	$ 16,175,000

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Compensation	$ 14	$ 1
Professional fees	94	169
Clinical trial expenses	61	61
Other expenses	159	207
Accrued expenses	$ 328	$ 438

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 2,353	$ 6,253
Less: accumulated depreciation	(2,216)	(2,206)
Property and equipment, net	137	4,047
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		3,900
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 2,353	$ 2,353

Property and Equipment, net (De

Property and Equipment, net (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 10,000	$ 162,000
Impairment charges			$ 1,800,000

Schedule of Patents, Trademark

Schedule of Patents, Trademark Rights (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning balance	$ 1,974	$ 1,498	$ 1,498
Acquisitions	33		592
Amortization	(19)	$ (65)	(116)
Ending balance	$ 1,988		$ 1,974

Schedule of Amortization of Pat

Schedule of Amortization of Patents and Trademarks (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 59
2023	153
2024	177
2025	199
2026	235
Thereafter	1,165
Total	$ 1,988	$ 1,974	$ 1,498

Patents (Details Narrative)

Patents (Details Narrative)	3 Months Ended
	Mar. 31, 2022
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and trademarks estimated useful life	17 years

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Jul. 07, 2020	Sep. 27, 2019	Sep. 12, 2018	Dec. 31, 2020	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 16, 2018
Class of Stock [Line Items]
Preferred stock, shares authorized					5,000,000
Preferred stock stated value					$ 0.01
Warrant exercise price										$ 17.05
Warrants and rights outstanding term										5 years
Common stock, shares authorized					350,000,000	350,000,000		350,000,000
Common stock shares with specific limitations and restrictions on usage					8,000,000
Common stock shares issued, value							$ 12,887,000
Warrants issued										73,314
Warrant outstanding					15,000
Number of options granted					300,000		0
Common stock, shares outstanding					47,994,672	47,994,672		47,994,672
Director [Member]
Class of Stock [Line Items]
Option vested years			10 years
2018 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Number of stock is reserved for potential issuance			7,000,000
2018 Equity Incentive Plan [Member] | Employees [Member]
Class of Stock [Line Items]
Number of options granted				675,000	300,000	613,512
Option exercise price per share					$ 0.70
Expiration period				10 years	10 years	10 years
Pre-funded Warrants [Member]
Class of Stock [Line Items]
Shares issued price per share		$ 0.899
Warrant [Member]
Class of Stock [Line Items]
Warrant exercise price		$ 0.99
Alliance Global Partners, LLC [Member]
Class of Stock [Line Items]
Number of shares issued upon transaction		1,740,550
Warrants issued		7,148,310
Proceeds from Issuance or Sale of Equity		$ 7,200,000
Alliance Global Partners, LLC [Member] | Warrants [Member]
Class of Stock [Line Items]
Number of warrant to purchase shares of common stock		8,888,860
Alliance Global Partners, LLC [Member] | Pre-funded Warrants [Member]
Class of Stock [Line Items]
Shares issued price per share		$ 0.90
Maxim Group LLC [Member] | Equity Distribution Agreement [Member]
Class of Stock [Line Items]
Proceeds from Issuance or Sale of Equity								$ 13,301,526	$ 53,936,615
Sale of stock, Number of shares issued								5,665,731	20,444,807
Shares sales fee percentage				3.50%		3.50%		3.50%	3.50%
Underwriting fee amount.								$ 465,533	$ 1,888,727
Minimum [Member] | 2018 Equity Incentive Plan [Member] | Employees [Member]
Class of Stock [Line Items]
Option exercise price per share				$ 1.85		$ 1.11
Maximum [Member] | 2018 Equity Incentive Plan [Member] | Employees [Member]
Class of Stock [Line Items]
Option exercise price per share				$ 1.96		1.71
Maximum [Member] | Alliance Global Partners, LLC [Member] | Representative Warrants [Member]
Class of Stock [Line Items]
Number of warrant to purchase shares of common stock		266,665
Directors, Officers and Employees [Member]
Class of Stock [Line Items]
Common stock shares issued, value	$ 500,000
Rights [Member]
Class of Stock [Line Items]
Warrant exercise price					$ 1,000
Proceeds from warrants					$ 4,700,000
Warrant [Member]
Class of Stock [Line Items]
Warrant exercise price					$ 8.80
Warrants and rights outstanding term					5 years
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					250,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					8,000
Preferred stock stated value					$ 1,000	$ 1,000		$ 1,000
Preferred Stock, No Par Value					$ 0
Preferred Stock, Shares Outstanding					715	715		715
Series B Convertible Preferred Stock [Member] | Rights [Member]
Class of Stock [Line Items]
Preferred stock face value					$ 1,000
Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares to be issued on conversion					114	114		114
Common Stock [Member]
Class of Stock [Line Items]
Common stock shares issued, value								$ 205,000
Number of shares issued upon transaction					0			132,238
Common Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Shares issued price per share						$ 1.16		$ 1.16
Common Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Shares issued price per share						$ 2.35		$ 2.35

Schedule of Assumptions to Esti

Schedule of Assumptions to Estimate Fair Value of Warrants (Details)	Mar. 31, 2022$ / shares	Dec. 31, 2021$ / shares	Mar. 16, 2018
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term			5 years
February 2017 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 1.06	$ 0.92
February 2017 Warrants [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	30.25	30.25
February 2017 Warrants [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	33	33
February 2017 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0.71	0.22
February 2017 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0.74	0.23
February 2017 Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	4 months 2 days	6 months 29 days
February 2017 Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	4 months 6 days	7 months 6 days
February 2017 Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	85	45
February 2017 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield
June Two Thousand Seventeen Warrants[Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 1.06	$ 0.92
June Two Thousand Seventeen Warrants[Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	27.50	27.50
June Two Thousand Seventeen Warrants[Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	0.35	0.15
June Two Thousand Seventeen Warrants[Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	2 months 1 day	5 months 1 day
June Two Thousand Seventeen Warrants[Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	85	50
June Two Thousand Seventeen Warrants[Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield
April Two Thousand Eighteen Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 1.06	$ 0.92
April Two Thousand Eighteen Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	17.16	17.16
April Two Thousand Eighteen Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	2	0.67
April Two Thousand Eighteen Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	1 year 6 months 25 days	1 year 9 months 21 days
April Two Thousand Eighteen Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	70	120
April Two Thousand Eighteen Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield
March Two Thousand Nineteen Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Underlying price per share	$ 1.06	$ 0.92
March Two Thousand Nineteen Warrants [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	8.80	8.80
March Two Thousand Nineteen Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	2.24	0.78
March Two Thousand Nineteen Warrants [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant term	1 year 11 months 8 days	2 years 2 months 8 days
March Two Thousand Nineteen Warrants [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	75	125
March Two Thousand Nineteen Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield

Schedule of Range of Probabilit

Schedule of Range of Probabilities (Details)	3 Months Ended
	Mar. 31, 2022
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	0.50%
Weighted Average [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	1.00%
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of probability	5.00%

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 15,554	$ 16,175
Redeemable warrants	4	35
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	15,554	16,175
Redeemable warrants
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Redeemable warrants
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Redeemable warrants	$ 4	$ 35

Schedule of Changes in Level 3

Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis (Details) - Redeemable Warrants [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Balance at beginning	$ 35
Fair value adjustments	(31)
Balance at ending	$ 4

Schedule of Assets and Liabil_2

Schedule of Assets and Liabilities Measured at Fair Value on a NonRecurring Basis (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property plant and equipment	$ 3,900,000	[1]
Property plant and equipment	1,800,000	[1]
Property plant and equipment collections, not capitalized deaccessed fair value	3,900,000
Impairment of Long-Lived Assets to be Disposed of	1,800,000
Land, Buildings and Improvements [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long lived assets held for sale carrying amount	5,700,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property plant and equipment		[1]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property plant and equipment		[1]
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property plant and equipment	$ 3,900,000	[1]
[1]	In accordance with Subtopic 360-10, long-lived assets held and used with a carrying amount of $ 5,700,000 3,900,000 1,800,000

Fair Value (Details Narrative)

Fair Value (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Floor rate used as proxy for future volatility percentage	100.00%
Fair value adjustment of warrants	$ (31,000)	$ 37,000
Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value adjustment of warrants	$ 4,000		$ 35,000
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurement, input percentage	0.00%

Financing Obligation Arising _2

Financing Obligation Arising from Sale Leaseback Transaction (Details Narrative) - USD ($)	May 13, 2021	Mar. 16, 2018	Mar. 31, 2022	Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of buildings		$ 4,080,000
Lease and property agreement description		lease the property back for ten years at $408,000 per year for two years through March 31, 2020. The lease payments would increase 2.5% per year for the next three years through March 31, 2023, and the lease payments would increase 3% for the remaining five years through March 31, 2028
Warrants term		5 years
Warrant to purchase of common stock		73,314
Warrant exercise price per share		$ 17.05
Warrant closing price, percentage		125.00%
Repurchase of property	$ 4,732,637
Financing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Interest expense			$ 0	$ 14,000

Schedule of Operating lease Fut

Schedule of Operating lease Future Payments (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Leases
2022	$ 49,000
2023	60,000
2024	35,000
2025	14,000
Less imputed interest	(14,000)
Total	$ 144,000	$ 149,000

Leases (Details Narrative)

Leases (Details Narrative)	Feb. 17, 2022USD ($)	Sep. 14, 2020USD ($)	May 01, 2019USD ($)ft²	Jun. 13, 2018USD ($)ft²	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)
Weighted average remaining term					3 years 8 months 12 days	2 years 8 months 19 days
Incremental borrowing rate					0.10	0.10
Right of use asset					$ 144,000	$ 149,000
Operating lease liability					144,000	149,000
Rent expenses					17,000	67,000
Short term lease rent expense					$ 3,000	$ 12,000
Lease Agreement [Member]
Lease agreement term			3 years
Lease commenced date			May 1, 2019
Base rent per month	$ 322		$ 2,500
Rentable area | ft²			3,000
Lease Agreement [Member] | Fraser Advanced Information Systems [Member]
Lease agreement term		5 years
Lease commenced date		Sep. 14, 2020
Base rent per month		$ 1,415
Lease Agreement [Member] | SML FL Holdings LLC [Member]
Lease agreement term				6 years
Lease commenced date				Jul. 1, 2018
Rentable area | ft²				3,000
Percentage of base rent				3.00%
Lease Agreement [Member] | SML FL Holdings LLC [Member] | First Year [Member]
Base rent per month				$ 2,100
Lease Agreement [Member] | SML FL Holdings LLC [Member] | Sixth Year [Member]
Base rent per month				$ 2,785
Minimum [Member]
Operating lease term					1 year
Operating lease, remaining lease term					13 months
Maximum [Member]
Operating lease term					5 years
Operating lease, remaining lease term					5 months

Research, Consulting and Supp_2

Research, Consulting and Supply Agreements (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended			12 Months Ended
	Apr. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Research and development expense			$ 1,036,000	$ 1,424,000
Centre for Human Drug Research [Member]
Research and consulting			1,010,000
Centre for Human Drug Research [Member] | Sponsor Agreement [Member] | Forecast [Member]
Research and consulting		$ 61,000
Polysciences Inc [Member]
Research and consulting			$ 51,390		$ 250,000
Amarex Clinical Research LLC [Member] | Subsequent Event [Member]
Research and development expense	$ 8,200,000
Research and development expense	$ 1,000,000
Estimated lives	4 years 7 months 6 days